Background—Reperfusion injury of ischemic myocardium has been attributed to neutrophil infiltration, inflammatory activation and cardiac necrosis/apoptosis. Serine protease inhibition with aprotinin is cardioprotective, but the mechanism is unknown. Methods and Results—We studied aprotinin in a rat model of myocardial ischemia for 20 minutes and reperfusion for 20 minutes, 8 hours or 24 hours. Aprotinin (20 000 IU/kg) given 5 minutes before reperfusion significantly reduced leukocyte accumulation (P0.01), myocardial injury (determined by CK depletion, P0.01) and myocyte apoptosis (P0.05) compared with vehicle treated rats. Differential gene expression analysis showed myocardial ischemia plus reperfusion increased expression of proinflammato...
© Schattauer 2015. Cardiac ischaemia and reperfusion leads to irreversible injury and subsequent tis...
Objective: The role of aprotinin in the prevention of lung reperfusion injury was investigated in th...
Bovine aprotinin, a reversible inhibitor of plasmin and kallikrein, has been clinically approved for...
AbstractObjective: Early coronary reperfusion of the ischemic myocardium is a desired therapeutic go...
ObjectiveThe purpose of the study was to determine the effects of aprotinin on (1) renal function, (...
Objectives: In addition to blood-sparing effects, aprotinin may have cardioprotective and anti-infla...
Background— Cardiac surgery with cardiopulmonary bypass (CPB) and cardioplegic arrest has been assoc...
AbstractObjective: Inflammatory cytokines, particularly tumor necrosis factor, contribute to myocard...
Aprotinin reduces blood loss after cardiac operations and decreases the bleeding time. The mechanism...
The effect of aprotinin, a protease inhibitor, on myocardial interleukin-8 (IL-8) production after i...
WOS: 000168918600021PubMed ID: 11376635Objective: Aprotinin, a non-specific serine protease inhibito...
AbstractBackground: Aprotinin is a serine protease inhibitor used extensively in cardiac operations ...
Clinical trials revealed beneficial effects of the broad-spectrum serine protease inhibitor aprotini...
Cardiotomy suction enhances inflammation and fibrinolysis during cardiopulmonary bypass (CPB). Aprot...
Clinical trials revealed beneficial effects of the broad-spectrum serine protease inhibitor aprotini...
© Schattauer 2015. Cardiac ischaemia and reperfusion leads to irreversible injury and subsequent tis...
Objective: The role of aprotinin in the prevention of lung reperfusion injury was investigated in th...
Bovine aprotinin, a reversible inhibitor of plasmin and kallikrein, has been clinically approved for...
AbstractObjective: Early coronary reperfusion of the ischemic myocardium is a desired therapeutic go...
ObjectiveThe purpose of the study was to determine the effects of aprotinin on (1) renal function, (...
Objectives: In addition to blood-sparing effects, aprotinin may have cardioprotective and anti-infla...
Background— Cardiac surgery with cardiopulmonary bypass (CPB) and cardioplegic arrest has been assoc...
AbstractObjective: Inflammatory cytokines, particularly tumor necrosis factor, contribute to myocard...
Aprotinin reduces blood loss after cardiac operations and decreases the bleeding time. The mechanism...
The effect of aprotinin, a protease inhibitor, on myocardial interleukin-8 (IL-8) production after i...
WOS: 000168918600021PubMed ID: 11376635Objective: Aprotinin, a non-specific serine protease inhibito...
AbstractBackground: Aprotinin is a serine protease inhibitor used extensively in cardiac operations ...
Clinical trials revealed beneficial effects of the broad-spectrum serine protease inhibitor aprotini...
Cardiotomy suction enhances inflammation and fibrinolysis during cardiopulmonary bypass (CPB). Aprot...
Clinical trials revealed beneficial effects of the broad-spectrum serine protease inhibitor aprotini...
© Schattauer 2015. Cardiac ischaemia and reperfusion leads to irreversible injury and subsequent tis...
Objective: The role of aprotinin in the prevention of lung reperfusion injury was investigated in th...
Bovine aprotinin, a reversible inhibitor of plasmin and kallikrein, has been clinically approved for...